Drugs for focal seizures

Comparison of efficacy of valproate and oxcarbazepine in children with self-limited epilepsy with centrotemporal spikes: a randomized control trial VO-SELECT trial - VO-SELECT

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067011

Enrollment

114

Registered

2024-05-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset

Interventions

Intervention1: oxcarbazepine: oral tablets at a dose of 15 mg/kg/day in two dived doses daily for 12 weeks Control Intervention1: valproate: oral tablets at a dose of 20 mg/kg/day in two dived doses d

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed cases of self-limited epilepsy with centrotemporal spikes

Exclusion criteria

Exclusion criteria: History of allergy to either study medication

Design outcomes

Primary

Measure	Time frame
Proportion of participants who remain seizure free in each groupTimepoint: At 12 weeks	—

Secondary

Measure	Time frame
Number of participants with adverse effects related to study medicationTimepoint: At 12 weeks	—

Countries

India

Contacts

Public ContactPrateek Kumar Panda

AIIMS, Rishikesh

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026